Page last updated: 2024-12-08

phenyl di-n-pentylphosphinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

phenyl di-n-pentylphosphinate: inhibitor of neuropathy target esterase (neurotoxic esterase) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID151930
SCHEMBL ID3229927
MeSH IDM0159988

Synonyms (10)

Synonym
pdnp
dipentylphosphoryloxybenzene
phenyl di-n-pentylphosphinate
14656-17-8
phosphinic acid, dipentyl-, phenyl ester
pdpp
TUJWIYZCAPMHSA-UHFFFAOYSA-N
phenyl dipentylphosphinate
SCHEMBL3229927
DTXSID40163406

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" This is compatible with the fact that inhibited NTE is autopsy material from hens dosed with PPP can always be reactivated in vitro, presumably because no 'aging' reaction has occurred."( Prophylaxis against and promotion of organophosphate-induced delayed neuropathy by phenyl di-n-pentylphosphinate.
Johnson, MK; Read, DJ, 1993
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (16.67)18.7374
1990's1 (8.33)18.2507
2000's0 (0.00)29.6817
2010's2 (16.67)24.3611
2020's7 (58.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.60 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]